High levels of Endo180 protein are detected in the majority of STS: 64.0% of rhabdomyosarcomas (126/197), 38.5% well-differentiated liposarcomas (20/52), 93.1% dedifferentiated liposarcomas (54/58), 64.2% leiomyosarcomas (97/151), 76.1% synovial sarcomas (32/42), 87.5% fibrosarcomas (21/24), and 64.3% of UPS (65/101; Fig. 1C). This evidence concerns the gene MRC2 and fibrosarcoma.